RVNC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RVNC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Revance Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was $0.565. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.72 for the trailing ten years ended in Mar. 2024.
During the past 12 months, Revance Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 67.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-05-21), Revance Therapeutics's current stock price is $3.01. Revance Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.72. Revance Therapeutics's Cyclically Adjusted PS Ratio of today is 4.18.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Revance Therapeutics was 105.44. The lowest was 4.19. And the median was 57.96.
The historical data trend for Revance Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revance Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | 0.43 | 0.51 | 0.58 | 0.66 | 0.72 |
For the Biotechnology subindustry, Revance Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Revance Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.565 | / | 131.7762 | * | 131.7762 | |
= | 0.565 |
Current CPI (Mar. 2024) = 131.7762.
Revance Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.004 | 100.560 | 0.005 |
201409 | 0.003 | 100.428 | 0.004 |
201412 | 0.003 | 99.070 | 0.004 |
201503 | 0.003 | 99.621 | 0.004 |
201506 | 0.003 | 100.684 | 0.004 |
201509 | 0.003 | 100.392 | 0.004 |
201512 | 0.003 | 99.792 | 0.004 |
201603 | 0.003 | 100.470 | 0.004 |
201606 | 0.003 | 101.688 | 0.004 |
201609 | 0.003 | 101.861 | 0.004 |
201612 | 0.003 | 101.863 | 0.004 |
201703 | 0.003 | 102.862 | 0.004 |
201706 | 0.003 | 103.349 | 0.004 |
201709 | 0.002 | 104.136 | 0.003 |
201712 | 0.001 | 104.011 | 0.001 |
201803 | 0.005 | 105.290 | 0.006 |
201806 | 0.019 | 106.317 | 0.024 |
201809 | 0.065 | 106.507 | 0.080 |
201812 | 0.013 | 105.998 | 0.016 |
201903 | 0.007 | 107.251 | 0.009 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | 0.001 | 108.329 | 0.001 |
201912 | 0.002 | 108.420 | 0.002 |
202003 | 0.001 | 108.902 | 0.001 |
202006 | 0.006 | 108.767 | 0.007 |
202009 | 0.063 | 109.815 | 0.076 |
202012 | 0.176 | 109.897 | 0.211 |
202103 | 0.200 | 111.754 | 0.236 |
202106 | 0.279 | 114.631 | 0.321 |
202109 | 0.291 | 115.734 | 0.331 |
202112 | 0.381 | 117.630 | 0.427 |
202203 | 0.370 | 121.301 | 0.402 |
202206 | 0.405 | 125.017 | 0.427 |
202209 | 0.402 | 125.227 | 0.423 |
202212 | 0.622 | 125.222 | 0.655 |
202303 | 0.564 | 127.348 | 0.584 |
202306 | 0.695 | 128.729 | 0.711 |
202309 | 0.656 | 129.860 | 0.666 |
202312 | 0.803 | 129.419 | 0.818 |
202403 | 0.565 | 131.776 | 0.565 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Revance Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 3.01 | / | 0.72 | |
= | 4.18 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Revance Therapeutics was 105.44. The lowest was 4.19. And the median was 57.96.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Revance Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Dwight Moxie | officer: SVP, GC & Secretary | 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Mark J Foley | director | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Tobin Schilke | officer: Chief Financial Officer | 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080 |
Carey Oconnor Kolaja | director | C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203 |
Dustin S Sjuts | officer: President | 7555 GATEWAY BLVD, NEWARK CA 94560 |
Vlad Coric | director | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Aubrey Rankin | director | C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560 |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Olivia C Ware | director | 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049 |
Chris Nolet | director | C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Jill Beraud | director | C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111 |
L Daniel Browne | director, officer: CEO and President | 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Cyril Allouche | officer: Principal Financial Officer | 7555 GATEWAY BLVD., NEWARK CA 94560 |
Lauren P Silvernail | officer: CFO, Seretary & EVP Corp Dev. | 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618 |
Caryn Gordon Mcdowell | officer: SVP, GC & Secretary | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Business Wire Business Wire • 02-21-2023
By Business Wire Business Wire • 05-02-2023
By GuruFocus Research GuruFocus Editor • 05-18-2023
By Business Wire • 09-19-2023
By Business Wire • 11-01-2023
By Business Wire Business Wire • 01-09-2023
By Business Wire • 10-26-2023
By PRNewswire • 10-18-2023
By Marketwired • 09-25-2023
By Business Wire Business Wire • 02-28-2023